Pneumococcal Vaccines Clinical Trial
Official title:
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Verified date | March 2024 |
Source | Vaxcyte, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
Status | Completed |
Enrollment | 835 |
Est. completion date | January 10, 2023 |
Est. primary completion date | January 10, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: - Male or female age 18 to 49 years (inclusive) for the Phase 1 group, or 50 to 64 years (inclusive) for the Phase 2 group at the time of enrollment into the study. - Able and willing to complete the informed consent process. - Available for clinical follow-up through the last study visit at 6 months after the study vaccination. - In good general health as determined by medical history, vital signs, physical examination, and clinical judgment of the investigator. - Screening laboratory values must be within the central laboratory normal limits prior to study enrollment. Minor abnormalities are considered acceptable if not clinically significant. - Willing to have blood samples collected, stored indefinitely, and used for research purposes. - Able to provide proof of identity to the satisfaction of the study staff completing the enrollment process. - Negative pregnancy test (urine and serum) for women of childbearing potential. Exclusion Criteria: - Previous pneumococcal disease (either confirmed or by self-reporting). - Previous receipt of a licensed or investigational pneumococcal vaccine. - Receipt of any investigational study product within 30 days prior to enrollment into the study, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study. - Planned or actual administration of any licensed vaccine during the period starting 30 days before enrollment into the study through Day 29. - Physical examination indicating any clinically significant medical condition. - Body Temperature > 38.0°C (> 100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescheduled). - Seropositive to HIV, HCV, or HBsAg. - History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis. - Female who is breast-feeding or planning to become pregnant during study participation. - Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws. - Any other chronic or clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject or confound evaluation of the study vaccine. - Any medical, psychiatric, or social condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent. - Received blood or blood product (including Immune Globulin IV) within 90 days prior to enrollment into the study. - Received systemic corticosteroids for = 14 consecutive days and has not completed treatment =30 days prior to enrollment into the study. - Receiving immunosuppressive therapy. - History of malignancy =5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. |
Country | Name | City | State |
---|---|---|---|
United States | CenExel RCA | Hollywood | Florida |
United States | Alliance for Multispecialty Research | Kansas City | Missouri |
United States | Johnson County Clin-Trials | Lenexa | Kansas |
United States | Benchmark Research | Metairie | Louisiana |
United States | Coastal Carolina Research | North Charleston | South Carolina |
United States | Rochester Clinical Research | Rochester | New York |
United States | JBR Clinical Research | Salt Lake City | Utah |
United States | Benchmark Research | San Angelo | Texas |
United States | Meridian Clinical Research | Savannah | Georgia |
United States | Precision Clinical Research | Sunrise | Florida |
United States | Velocity Clinical Research | Valparaiso | Indiana |
United States | Velocity Clinical Research | Warwick | Rhode Island |
United States | Acellacare of Wilmington | Wilmington | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Vaxcyte, Inc. |
United States,
Wassil J, Sisti M, Fairman J, Davis M, Fierro C, Bennett S, Johnson D, Migone TS, Nguyen K, Sauer P, Currie M, Iki S, Simon JK. Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adult — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Solicited local reactions include redness/erythema, swelling/induration, and pain at injection site within 7 days after vaccination in each age group | 7 days after vaccination | |
Primary | Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group | Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain | 7 days after vaccination | |
Primary | Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group | Percentage of participants in each age group with adverse events (AEs) whose date of onset occurs after the study vaccine and within the 28 days after vaccination. | 1 month after vaccination | |
Primary | Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI) | Percentage of participants with SAEs and NOCIs | 6 months after vaccination | |
Secondary | Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values | Shifts from Normal at Baseline to Abnormal on Day 29 in Clinical Chemistry Parameters Occurring in >5% of Subjects Aged 50 to 64 Years | 1 month after vaccination | |
Secondary | VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs) | Antibody geometric mean titers as measured by OPA for the 24 pneumococcal serotypes in VAX-24 | 1 month after vaccination | |
Secondary | VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) | Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24 | 1 month after vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01953510 -
Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam
|
Phase 2/Phase 3 | |
Completed |
NCT05540028 -
Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
|
Phase 1 | |
Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
Active, not recruiting |
NCT06077656 -
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
|
Phase 2 | |
Active, not recruiting |
NCT06151288 -
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT06000397 -
Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age
|
N/A | |
Completed |
NCT00574548 -
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
|
Phase 3 | |
Not yet recruiting |
NCT06271681 -
Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
|
Phase 4 | |
Active, not recruiting |
NCT05844423 -
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
|
Phase 2 | |
Completed |
NCT00824655 -
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
|
Phase 3 | |
Completed |
NCT01646398 -
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
|
Phase 3 | |
Completed |
NCT00464945 -
Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
|
Phase 3 | |
Completed |
NCT03893448 -
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
|
Phase 3 | |
Completed |
NCT05297578 -
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
|
Phase 2 | |
Completed |
NCT01964716 -
13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
|
Phase 3 | |
Completed |
NCT01537185 -
Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT00999739 -
Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
|
Phase 3 | |
Not yet recruiting |
NCT05721456 -
Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil.
|
Phase 3 | |
Active, not recruiting |
NCT02012309 -
Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
|
N/A | |
Completed |
NCT01392378 -
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
|
Phase 4 |